DE69739843D1 - Verfahren zur herstellung einer verbindung durch polymerisierung einer modelldroge - Google Patents

Verfahren zur herstellung einer verbindung durch polymerisierung einer modelldroge

Info

Publication number
DE69739843D1
DE69739843D1 DE69739843T DE69739843T DE69739843D1 DE 69739843 D1 DE69739843 D1 DE 69739843D1 DE 69739843 T DE69739843 T DE 69739843T DE 69739843 T DE69739843 T DE 69739843T DE 69739843 D1 DE69739843 D1 DE 69739843D1
Authority
DE
Germany
Prior art keywords
nucleic acid
forming
polymerizing
compound
producing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69739843T
Other languages
English (en)
Inventor
Jon A Wolff
James E Hagstrom
Vladimir G Budker
Vladimer S Trubetskoy
Paul M Slattum
Lisa J Hanson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arrowhead Madison Inc
Original Assignee
Mirus Bio Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mirus Bio Corp filed Critical Mirus Bio Corp
Application granted granted Critical
Publication of DE69739843D1 publication Critical patent/DE69739843D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
DE69739843T 1997-01-03 1997-12-30 Verfahren zur herstellung einer verbindung durch polymerisierung einer modelldroge Expired - Lifetime DE69739843D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/778,657 US6126964A (en) 1996-01-04 1997-01-03 Process of making a compound by forming a polymer from a template drug
PCT/US1997/024089 WO1998029541A1 (en) 1997-01-03 1997-12-30 A process of making a compound by forming a polymer from a template drug

Publications (1)

Publication Number Publication Date
DE69739843D1 true DE69739843D1 (de) 2010-05-27

Family

ID=25114039

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69739843T Expired - Lifetime DE69739843D1 (de) 1997-01-03 1997-12-30 Verfahren zur herstellung einer verbindung durch polymerisierung einer modelldroge

Country Status (6)

Country Link
US (8) US6126964A (de)
EP (1) EP0958356B1 (de)
AT (1) ATE464377T1 (de)
DE (1) DE69739843D1 (de)
ES (1) ES2340006T3 (de)
WO (1) WO1998029541A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5674908A (en) 1993-12-20 1997-10-07 Life Technologies, Inc. Highly packed polycationic ammonium, sulfonium and phosphonium lipids
US6989434B1 (en) 1994-02-11 2006-01-24 Invitrogen Corporation Reagents for intracellular delivery of macromolecules
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US20030069173A1 (en) * 1998-03-16 2003-04-10 Life Technologies, Inc. Peptide-enhanced transfections
US6126964A (en) * 1996-01-04 2000-10-03 Mirus Corporation Process of making a compound by forming a polymer from a template drug
EP1073707A4 (de) * 1998-04-30 2002-03-13 Mirus Corp Verfahren zur herstellung einer verbindung durch polymerisierung einer modelldroge
US7396919B1 (en) * 1998-07-17 2008-07-08 Mirus Bio Corporation Charge reversal of polyion complexes
ATE383331T1 (de) 1998-11-12 2008-01-15 Invitrogen Corp Transportreagentien
CA2368801A1 (en) * 1999-04-30 2000-11-09 Slil Biomedical Corporation Conjugates as therapies for cancer and prostate diseases
NZ515140A (en) * 1999-04-30 2003-07-25 Slil Biomedical Corp Conformationally restricted polyamine analogs as disease therapies for cancer, epilepsy, alzheimers, infections, grafts and others
WO2000075164A1 (en) * 1999-06-07 2000-12-14 Mirus Corporation COMPOSITIONS AND METHODS FOR DRUG DELIVERY USING pH SENSITIVE MOLECULES
US6770740B1 (en) 1999-07-13 2004-08-03 The Regents Of The University Of Michigan Crosslinked DNA condensate compositions and gene delivery methods
AU785007B2 (en) * 1999-11-24 2006-08-24 Mcs Micro Carrier Systems Gmbh Polypeptides comprising multimers of nuclear localization signals or of protein transduction domains and their use for transferring molecules into cells
US6881576B2 (en) * 1999-12-31 2005-04-19 Mirus Bio Corporation Formation of polyampholytes in the presence of a polyion
US20020042388A1 (en) * 2001-05-01 2002-04-11 Cooper Mark J. Lyophilizable and enhanced compacted nucleic acids
WO2002091989A2 (en) * 2000-11-08 2002-11-21 Slil Biomedical Corporation Antiviral therapies using polyamine or polyamine analog-amino acid conjugates
US20030096414A1 (en) 2001-03-27 2003-05-22 Invitrogen Corporation Culture medium for cell growth and transfection
CA2463771A1 (en) * 2001-10-16 2003-04-24 Slil Biomedical Corporation Oligoamine compounds and derivatives thereof for cancer therapy
US20040063654A1 (en) * 2001-11-02 2004-04-01 Davis Mark E. Methods and compositions for therapeutic use of RNA interference
JP2005527639A (ja) * 2001-11-02 2005-09-15 インサート セラピューティクス インコーポレイテッド Ｒｎａ干渉の治療的利用のための方法及び組成物
DE60328383D1 (de) 2002-05-24 2009-08-27 Mirus Bio Corp Zusammensetzungen zur zuführung von nukleinsäuren an zellen
US7348453B2 (en) * 2003-09-04 2008-03-25 Mirus Bio Corporation Labile linkage for compound delivery to a cell
SG131946A1 (en) * 2003-10-24 2007-05-28 Hoffmann La Roche Ccr3 receptor antagonists
US20060229267A1 (en) 2004-06-01 2006-10-12 Reza Sheikhnejad Methods and compositions for the inhibition of gene expression
US8172855B2 (en) 2004-11-24 2012-05-08 Abdou M S Devices and methods for inter-vertebral orthopedic device placement
JP5014572B2 (ja) * 2004-12-20 2012-08-29 正彦 阿部 重合性界面活性剤およびその製造方法
ES2548240T3 (es) 2005-12-01 2015-10-15 Pronai Therapeutics, Inc. Terapias para el cáncer y composiciones farmacéuticas usadas en las mismas
TWI428135B (zh) * 2007-03-26 2014-03-01 Hirofumi Takeuchi And a carrier composition for quick-acting nucleic acid delivery
CN101270168B (zh) * 2008-05-13 2011-06-22 中国药科大学 透明质酸接枝聚乙烯亚胺共聚物、制备方法及其作为基因载体的应用
US8950583B2 (en) 2008-12-06 2015-02-10 Ermes Medical Company Limited Method to remove heavy metals from a mammal
ES2542874T3 (es) 2009-03-04 2015-08-12 Hirofumi Takeuchi Complejo de ácidos nucleicos y composición de administración de ácidos nucleicos
US8921448B1 (en) * 2009-09-07 2014-12-30 Mirus Bio Llc Transfection compositions using amphipathic compounds
IN2012DN02586A (de) * 2009-09-28 2015-08-28 Univ Kentucky Res Found
US8575218B2 (en) * 2009-09-28 2013-11-05 The University Of Kentucky Research Foundation Thiol-containing compounds for the removal of elements from tissues and formulations therefor
US8764806B2 (en) 2009-12-07 2014-07-01 Samy Abdou Devices and methods for minimally invasive spinal stabilization and instrumentation
US20110237776A1 (en) * 2010-03-25 2011-09-29 Haley Boyd E Aromatic compounds with sulfur containing ligands
US8426368B2 (en) * 2010-03-25 2013-04-23 The University Of Kentucky Research Foundation Method of ameliorating oxidative stress and supplementing the diet
JP2013528665A (ja) 2010-03-26 2013-07-11 メルサナ セラピューティックス， インコーポレイテッド ポリヌクレオチドの送達のための修飾ポリマー、その製造方法、およびその使用方法
US8845728B1 (en) 2011-09-23 2014-09-30 Samy Abdou Spinal fixation devices and methods of use
US20130226240A1 (en) 2012-02-22 2013-08-29 Samy Abdou Spinous process fixation devices and methods of use
US9198767B2 (en) 2012-08-28 2015-12-01 Samy Abdou Devices and methods for spinal stabilization and instrumentation
US9320617B2 (en) 2012-10-22 2016-04-26 Cogent Spine, LLC Devices and methods for spinal stabilization and instrumentation
EP2914742A1 (de) 2012-11-05 2015-09-09 Pronai Therapeutics, Inc. Verfahren zur verwendung von biomarkern zur behandlung von krebs durch modulation der bcl2-expression
EP3169310A1 (de) 2014-07-15 2017-05-24 Life Technologies Corporation Zusammensetzungen mit lipidaggregaten und verfahren zur effizienten bereitstellung von molekülen an zellen
US10857003B1 (en) 2015-10-14 2020-12-08 Samy Abdou Devices and methods for vertebral stabilization
US10973648B1 (en) 2016-10-25 2021-04-13 Samy Abdou Devices and methods for vertebral bone realignment
US10744000B1 (en) 2016-10-25 2020-08-18 Samy Abdou Devices and methods for vertebral bone realignment
US10303608B2 (en) * 2017-08-22 2019-05-28 Qualcomm Incorporated Intelligent data prefetching using address delta prediction
US11179248B2 (en) 2018-10-02 2021-11-23 Samy Abdou Devices and methods for spinal implantation
US11724260B2 (en) 2019-04-08 2023-08-15 The Regents Of The University Of Michigan Microfluidic sensor

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223424A (en) * 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US4861719A (en) * 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
US5585481A (en) * 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
US5149543A (en) * 1990-10-05 1992-09-22 Massachusetts Institute Of Technology Ionically cross-linked polymeric microcapsules
US5270170A (en) * 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US6113946A (en) * 1992-04-03 2000-09-05 The Regents Of The University Of California Self-assembling polynucleotide delivery system comprising dendrimer polycations
US5562909A (en) * 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US6232295B1 (en) * 1994-10-12 2001-05-15 Jon Faiz Kayyem Cell-specific contrast agent and gene delivery vehicles
US6126964A (en) * 1996-01-04 2000-10-03 Mirus Corporation Process of making a compound by forming a polymer from a template drug
AU739969B2 (en) * 1996-05-29 2001-10-25 Cell Genesys, Inc. Cationic polymer/lipid nucleic acid delivery vehicles

Also Published As

Publication number Publication date
US20060024828A1 (en) 2006-02-02
US6706922B2 (en) 2004-03-16
EP0958356B1 (de) 2010-04-14
US20020061287A1 (en) 2002-05-23
US20060159764A1 (en) 2006-07-20
EP0958356A4 (de) 2008-03-05
US6960690B2 (en) 2005-11-01
ES2340006T3 (es) 2010-05-27
US7022525B2 (en) 2006-04-04
ATE464377T1 (de) 2010-04-15
US20020165184A1 (en) 2002-11-07
US6339067B1 (en) 2002-01-15
US20040161463A1 (en) 2004-08-19
WO1998029541A1 (en) 1998-07-09
US20020085989A1 (en) 2002-07-04
US7482160B2 (en) 2009-01-27
EP0958356A1 (de) 1999-11-24
US7049144B2 (en) 2006-05-23
US6126964A (en) 2000-10-03

Similar Documents

Publication Publication Date Title
ATE464377T1 (de) Verfahren zur herstellung einer verbindung durch polymerisierung einer modelldroge
ATE219881T1 (de) Verfahren zur herstellung antimikrobieller kunststoffe
DE68916707D1 (de) Verfahren zur Herstellung eines hydrophilen Polymers.
DE3668553D1 (de) Waessrige zusammensetzung, verfahren zur herstellung eines wasserabsorbierenden polymers und eines damit ueberzogenen gegenstandes.
DE69916834D1 (de) Verfahren zur polymerisation von olefinen unter verwendung von aktivierten lewis säure-base komplexen
DE3876557D1 (de) Verfahren zur herstellung waessriger polymerdispersionen.
DE69511491D1 (de) Verfahren zur Herstellung eines Polymers durch Lösungspolymerisation
ATE220291T1 (de) Verfahren zur herstellung antimikrobieller kunststoffe
DE3769665D1 (de) Verfahren und vorrichtung zur formgebung mit hilfe eines festen, fliessfaehigen polymers.
DE3750290T2 (de) Verfahren zur Herstellung eines druckempfindlichen Acrylat Polymer-Klebstoffes mit vermindertem Restmonomergehalt.
DE60118007D1 (de) Verfahren zur herstellung von blockcopolymeren durch eine kontrollierte radikalpolymerisation in gegenwart von einer disulfidverbindung
ATE154042T1 (de) Verfahren zur herstellung von stern- oder netzwerk-multiblockpolykondensaten durch kupplung von di- oder multi-aldehyden und damit hergestellten polykondensaten
DE59607205D1 (de) Verfahren zur Herstellung von stabilisierten Olefinpolymeren
DE68908490T2 (de) Verfahren zur Herstellung eines Wasser absorbierenden Polymers.
ATE289703T1 (de) Verfahren zur herstellung von pi-konjugierten polymeren
ATE243225T1 (de) Verfahren zur herstellung von im alkalischen löslichen copolymerisaten auf (meth) acrylatbasis
DE3874281D1 (de) Verfahren zur herstellung von funktionalisierten polymeren.
DE69018440T2 (de) Verfahren zur herstellung von hyaluronsäure mit niedrigem molekulargewicht.
DE60119914D1 (de) Verfahren zur herstellung von zusammensetzungen mit beschleunigter abgabe unter verwendung von komprimierten fluiden
DE3677334D1 (de) Verfahren zur herstellung eines polymers einer alpha,beta-ungesaettigten karbonsaeure.
DE50112718D1 (de) Verfahren zur herstellung von übergangsmetallverbindungen und deren verwendung zur polymerisation von olefinen
DE3674484D1 (de) Verfahren zur kupplung von lebenden polymeren erhalten durch anionische polymerisation.
DE3877324D1 (de) Verfahren zur herstellung von acrylamidomethansulfonsaeure-polymeren.
DE69404454T2 (de) Verfahren zur herstellung von aminomethanphosphonsäure
ATE279452T1 (de) Katalysator für die additionspolymerisation und verfahren zur herstellung eines additionspolymers mit diesem katalysator

Legal Events

Date Code Title Description
8364 No opposition during term of opposition